Vivos Inc (RDGL) company profile

Vivos Inc. is a radiation oncology medical device company focused on developing precision radionuclide therapy products. Its core technologies utilize yttrium-90 (Y-90) and include RadioGel for treating solid tumors and positive surgical margins in humans, alongside IsoPet for targeting solid tumors in veterinary patients. The company operates through human and animal therapy divisions, with the latter providing direct treatments and clinic certifications. It also sells PLGA-g-PEG polymers and PrecisionGel, a hydrogel platform designed for delivering active pharmaceutical ingredients and therapeutic agents.

The company is headquartered in Kennewick, Washington. Its operations encompass clinical collaborations across multiple university veterinary hospitals and research laboratories within the United States. In addition, the firm conducts clinical testing activities and is establishing international operations in India through a wholly owned subsidiary based in Mumbai. Domestic production facilities are located in Richland, Washington, serving both animal and human therapy product lines.

Summary of the business section of Vivos's latest annual report, written by StockData.

“Since 2017, the Company has followed the cost-effective model of having had one full-time employee, the CEO.”